These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 14676110)

  • 1. Phase II study of imatinib in patients with small cell lung cancer.
    Johnson BE; Fischer T; Fischer B; Dunlop D; Rischin D; Silberman S; Kowalski MO; Sayles D; Dimitrijevic S; Fletcher C; Hornick J; Salgia R; Le Chevalier T
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5880-7. PubMed ID: 14676110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
    Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
    J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
    Chao J; Budd GT; Chu P; Frankel P; Garcia D; Junqueira M; Loera S; Somlo G; Sato J; Chow WA
    Anticancer Res; 2010 Feb; 30(2):547-52. PubMed ID: 20332468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is KIT an important therapeutic target in small cell lung cancer?
    Heinrich MC
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5825-8. PubMed ID: 14676102
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.
    Einhorn LH; Brames MJ; Heinrich MC; Corless CL; Madani A
    Am J Clin Oncol; 2006 Feb; 29(1):12-3. PubMed ID: 16462496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kit expression in small cell carcinomas of the lung: effects of chemotherapy.
    Rossi G; Cavazza A; Marchioni A; Migaldi M; Bavieri M; Facciolongo N; Petruzzelli S; Longo L; Tamberi S; Crinò L
    Mod Pathol; 2003 Oct; 16(10):1041-7. PubMed ID: 14559988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial.
    Altundag O; Altundag K; Boruban C; Silay YS; Turen S
    Cancer; 2005 Nov; 104(9):2033-4; author reply 2034. PubMed ID: 16161057
    [No Abstract]   [Full Text] [Related]  

  • 10. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
    Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
    J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
    Dy GK; Miller AA; Mandrekar SJ; Aubry MC; Langdon RM; Morton RF; Schild SE; Jett JR; Adjei AA
    Ann Oncol; 2005 Nov; 16(11):1811-6. PubMed ID: 16087693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
    Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
    Bond M; Bernstein ML; Pappo A; Schultz KR; Krailo M; Blaney SM; Adamson PC
    Pediatr Blood Cancer; 2008 Feb; 50(2):254-8. PubMed ID: 17262795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.
    Micke P; Basrai M; Faldum A; Bittinger F; Rönnstrand L; Blaukat A; Beeh KM; Oesch F; Fischer B; Buhl R; Hengstler JG
    Clin Cancer Res; 2003 Jan; 9(1):188-94. PubMed ID: 12538468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib in small cell lung cancer.
    Soria JC; Johnson BE; Chevalier TL
    Lung Cancer; 2003 Aug; 41 Suppl 1():S49-53. PubMed ID: 12867062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
    Baruchel S; Sharp JR; Bartels U; Hukin J; Odame I; Portwine C; Strother D; Fryer C; Halton J; Egorin MJ; Reis RM; Martinho O; Stempak D; Hawkins C; Gammon J; Bouffet E
    Eur J Cancer; 2009 Sep; 45(13):2352-9. PubMed ID: 19505817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
    Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
    Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of KIT expression in small cell lung cancer.
    López-Martin A; Ballestín C; Garcia-Carbonero R; Castaño A; Lopez-Ríos F; López-Encuentra A; Sánchez-Cespedes M; Castellano D; Bartolomé A; Cortés-Funes H; Paz-Ares L
    Lung Cancer; 2007 Jun; 56(3):405-13. PubMed ID: 17420067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.